Concussion, Mild Clinical Trial
Official title:
Randomized Controlled Trial of Targeted Treatment in Older Adults Following Concussion
The purpose of this study is to conduct the first randomized control trial for targeted treatments for concussion in adults 50 years or older. Participants will be enrolled at their first concussion clinical visit (V1) and their second study visit will occur after (up to 7 days) or concurrently with the participant's second concussion clinical visit, typically (but not limited to) between 21-31 days from V1.
| Status | Recruiting |
| Enrollment | 50 |
| Est. completion date | December 2024 |
| Est. primary completion date | December 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 50 Years to 99 Years |
| Eligibility | Inclusion Criteria: - 50 years of age or older - Diagnosed concussion within the last 4 days - 12 months - Must be recruited at their initial concussion appointment - Ability to read/write to complete study assessments/testing Exclusion Criteria: - Diagnosed neurological disorder (stroke, dementia, epilepsy) - Diagnosed major psychiatric disorders other than depression/anxiety (e.g., schizophrenia) - Diagnosed with moderate to severe brain injury or past brain surgery/malformations |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of Pittsburgh | Pittsburgh | Pennsylvania |
| Lead Sponsor | Collaborator |
|---|---|
| University of Pittsburgh |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Concussion Clinical Profiles Screening (CP Screen) | The CP Screen is a 29 item self-report, clinical profiles based symptom inventory that measures five concussion clinical profiles: 1) anxiety/mood, 2)cognitive/fatigue, 3) migraine, 4) ocular, 5) vestibular; and two modifying factors sleep and cervical. Participants indicate on a scale of 0 (none) to 3 (severe) the level of symptom severity for each item. The CP screen yields an average factor and modifier scores, with higher scores indicative of worse symptom severity, score range is 0-87. | Visit 1 (Baseline) | |
| Primary | Concussion Clinical Profiles Screening (CP Screen) | The CP Screen is a 29 item self-report, clinical profiles based symptom inventory that measures five concussion clinical profiles: 1) anxiety/mood, 2)cognitive/fatigue, 3) migraine, 4) ocular, 5) vestibular; and two modifying factors sleep and cervical. Participants indicate on a scale of 0 (none) to 3 (severe) the level of symptom severity for each item. The CP screen yields an average factor and modifier scores, with higher scores indicative of worse symptom severity, score range is 0-87. | At study completion, an average of 30 days after Visit 1 | |
| Secondary | Vestibular/Ocular Motor Screening (VOMS) | The VOMS assesses impairment via patient report symptom provocation following each of 5 test components (smooth pursuits, horizontal/vertical saccades, convergence, horizontal and vertical vestibular ocular reflex (VOR) and visual motor sensitivity (VMS). Patients verbally rate changes in headache, dizziness, nausea, and fogginess after each test, as well as report their baseline symptoms. Symptoms in each area are rated on scale 0 (none) to 10 (severe). Scores on any VOMS item of 2+ reflects a positive screening cut-off for vestibular and/or ocular motor impairment. | Visit 1 (Baseline) | |
| Secondary | Vestibular/Ocular Motor Screening (VOMS) | The VOMS assesses impairment via patient report symptom provocation following each of 5 test components (smooth pursuits, horizontal/vertical saccades, convergence, horizontal and vertical vestibular ocular reflex (VOR) and visual motor sensitivity (VMS). Patients verbally rate changes in headache, dizziness, nausea, and fogginess after each test, as well as report their baseline symptoms. Symptoms in each area are rated on scale 0 (none) to 10 (severe). Scores on any VOMS item of 2+ reflects a positive screening cut-off for vestibular and/or ocular motor impairment. | At study completion, an average of 30 days after Visit 1 | |
| Secondary | Short Falls Efficacy Scale (SFES) | The SFES is a 7 item survey that measures a subject's fear and concerns about falling during normal daily life activities. Question responses are scaled from 1-4, with higher scores indicating more concern for falls. (Low concern = 7-8; Moderate concern = 9-13; High concern = 14-28). | Visit 1 (Baseline) | |
| Secondary | Short Falls Efficacy Scale (SFES) | The SFES is a 7 item survey that measures a subject's fear and concerns about falling during normal daily life activities. Question responses are scaled from 1-4, with higher scores indicating more concern for falls. (Low concern = 7-8; Moderate concern = 9-13; High concern = 14-28). | At study completion, an average of 30 days after Visit 1 | |
| Secondary | Patient Health Questionnaire-9 (PHQ-9) | The PHQ-9 is a 9 item questionnaire that assesses the presence and severity of depression. Total score ranges from 1-27, with higher scores indicating higher level of depression. Scale is 0-4 (0=not at all, 1=several days, 2=more than half the days, 3=nearly every day). | Visit 1 (Baseline) | |
| Secondary | Patient Health Questionnaire-9 (PHQ-9) | The PHQ-9 is a 9 item questionnaire that assesses the presence and severity of depression. The PHQ-9 is a 9 item questionnaire that assesses the presence and severity of depression. Total score ranges from 1-27, with higher scores indicating higher level of depression. Scale is 0-4 (0=not at all, 1=several days, 2=more than half the days, 3=nearly every day). | At study completion, an average of 30 days after Visit 1 | |
| Secondary | Patient Health Questionnaire-15 (PHQ-15) | The PHQ-15 comprises 15 somatic symptoms that are scored from 0 ("not bothered at all") to 2 ("bothered a lot"). Higher scores are indicative of higher levels of depression (Minimal =0-4; Low = 5-9; Medium = 10-14; High = 15=30). | Visit 1 (Baseline) | |
| Secondary | Patient Health Questionnaire-15 (PHQ-15) | The PHQ-15 comprises 15 somatic symptoms that are scored from 0 ("not bothered at all") to 2 ("bothered a lot"). Higher scores are indicative of higher levels of depression (Minimal =0-4; Low = 5-9; Medium = 10-14; High = 15=30). | At study completion, an average of 30 days after Visit 1 | |
| Secondary | General Anxiety Disorder-7 (GAD-7) | The GAD-7 is a seven item self-reported questionnaire that measures severity of symptoms regarding anxiety. Responses are 0 = not at all, 1 = several days, 2= more than half the days, and 3 = nearly every day. Higher scores are indicative of higher anxiety (0-4 = minimal anxiety, 5-9= mild anxiety, 10-14 =moderate anxiety, 15-21 = severe anxiety. | Visit 1 (Baseline) | |
| Secondary | General Anxiety Disorder-7 (GAD-7) | The GAD-7 is a seven item self-reported questionnaire that measures severity of symptoms regarding anxiety. Responses are 0 = not at all, 1 = several days, 2= more than half the days, and 3 = nearly every day. Higher scores are indicative of higher anxiety (0-4 = minimal anxiety, 5-9= mild anxiety, 10-14 =moderate anxiety, 15-21 = severe anxiety. | At study completion, an average of 30 days after Visit 1 | |
| Secondary | PCL-5 | The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. Responses are on a 5 point likert scale (0=not at all, 1=a little bit, 2=moderately, 3=quite a bit, 4=extremely). Overall score is total sum of 20 items with higher scores indicating higher level of PTSD (Range 0-80) | Visit 1 (Baseline) | |
| Secondary | PCL-5 | The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. Responses are on a 5 point likert scale (0=not at all, 1=a little bit, 2=moderately, 3=quite a bit, 4=extremely). Overall score is total sum of 20 items with higher scores indicating higher level of PTSD (Range 0-80). | At study completion, an average of 30 days after Visit 1 | |
| Secondary | Neuro-QOL (Cognitive Function Scale - short form) | The cognitive function measures perceived difficulties in cognitive abilities (e.g., memory, attention, and decision making, or in the application of such abilities to everyday tasks (e.g., planning, organizing, calculating, remembering and learning). The short form contains 8 items, scored 0-5 (5=never, 4=rarely/once, 3=sometimes/2-3 times, 2=often/once a day, 1=very often/several times per day. Total scores range from 0-40. Higher scores indicate better self-reported cognitive function. | Visit 1 (Baseline) | |
| Secondary | Neuro-QOL (Cognitive Function Scale - short form) | The cognitive function measures perceived difficulties in cognitive abilities (e.g., memory, attention, and decision making, or in the application of such abilities to everyday tasks (e.g., planning, organizing, calculating, remembering and learning). The short form contains 8 items, scored 0-5 (5=never, 4=rarely/once, 3=sometimes/2-3 times, 2=often/once a day, 1=very often/several times per day. Total scores range from 0-40. Higher scores indicate better self-reported cognitive function. | At study completion, an average of 30 days after Visit 1 | |
| Secondary | Dizziness Handicap Inventory (DHI) | The DHI is a 25 item self-reported measure that examines dizziness-related handicap. The assessment has 3 domains (functional, emotional, and physical). Participants self-report the level dizziness has impacted their abilities in the 3 domains with each domain having 9 questions (questions are answered No (0)/Sometimes(2)/Yes(4)) Item scores are summed. There is a maximum score of 100 (28 points for physical, 36 points for emotional and 36 points for functional). Minimum score is 0. | Visit 1 (Baseline) | |
| Secondary | Dizziness Handicap Inventory (DHI) | The DHI is a 25 item self-reported measure that examines dizziness-related handicap. The assessment has 3 domains (functional, emotional, and physical). Participants self-report the level dizziness has impacted their abilities in the 3 domains with each domain having 9 questions (questions are answered No (0)/Sometimes(2)/Yes(4)) Item scores are summed. There is a maximum score of 100 (28 points for physical, 36 points for emotional and 36 points for functional). Minimum score is 0. | At study completion, an average of 30 days after Visit 1 | |
| Secondary | Headache Impact Test-6 (HIT-6) | The HIT-6 is comprised of 6 self-report items that assess frequency, severity and limitations of daily activities, fatigue, irritability, and concentration related to headaches. Items score from 6 to 13, with higher scores indicating worse severity. Scores = never = 6pts, rarely = 8 pts, sometimes = 10pts, very often = 11 pts, always = 13 points. Score range 36-78. | Visit 1 (Baseline) | |
| Secondary | Headache Impact Test-6 (HIT-6) | The HIT-6 is comprised of 6 self-report items that assess frequency, severity and limitations of daily activities, fatigue, irritability, and concentration related to headaches. Items score from 6 to 13, with higher scores indicating worse severity. Scores = never = 6pts, rarely = 8 pts, sometimes = 10pts, very often = 11 pts, always = 13 points. Score range 36-78. | At study completion, an average of 30 days after Visit 1 | |
| Secondary | ID Migraine | The ID Migraine will be used to screen for headache symptoms. It is a 3 item screening tool designed to assess presence (yes/no) of symptoms related to headache/migraine pain. Scores range from 0-3 with clinical cut-off of 2+ indicating presence of migraines. | Visit 1 (Baseline) | |
| Secondary | ID Migraine | The ID Migraine will be used to screen for headache symptoms. It is a 3 item screening tool designed to assess presence (yes/no) of symptoms related to headache/migraine pain. Scores range from 0-3 with clinical cut-off of 2+ indicating presence of migraines. | At study completion, an average of 30 days after Visit 1 | |
| Secondary | Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) | RBANS provides a brief, individually administered battery to measure cognitive decline or improvement across 5 domains (Immediate memory, visuospatial/constructional, language, attention, and delayed memory. There are total scores and indices scores, which are different depending on age and gender. Higher scores indicate better performance for all 5 domains. (<69=extremely low, 70-79=borderline, 80-89-low average, 90-109=average, 110-119=high average, 120-129=superior, 130 and higher = very superior). | Visit 1 (Baseline) | |
| Secondary | Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) | RBANS provides a brief, individually administered battery to measure cognitive decline or improvement across 5 domains (Immediate memory, visuospatial/constructional, language, attention, and delayed memory. There are total scores and indices scores, which are different depending on age and gender. Higher scores indicate better performance for all 5 domains. (<69=extremely low, 70-79=borderline, 80-89-low average, 90-109=average, 110-119=high average, 120-129=superior, 130 and higher = very superior). | At study completion, an average of 30 days after Visit 1 | |
| Secondary | Neck Disability Index | Neck pain scale, each item scores 0-5 with range 0-50. Overall score out of 50 is multiplied by 100 to get a percentage. 0-20% = minimal disability, 20-40% is moderate disability, 40-60% severe disability, 60-80% = crippled, 80-100% =participants are either bed-bound or exaggerating symptoms. | Visit 1 (Baseline) | |
| Secondary | Neck Disability Index | Neck pain scale, each item scores 0-5 with range 0-50. Overall score out of 50 is multiplied by 100 to get a percentage. 0-20% = minimal disability, 20-40% is moderate disability, 40-60% severe disability, 60-80% = crippled, 80-100% =participants are either bed-bound or exaggerating symptoms. | At study completion, an average of 30 days after Visit 1 | |
| Secondary | Pittsburgh Sleep Quality Index (PSQI) | The PSQI assesses sleep quality. It is an 19 item self-reported measure that is comprised of seven component scores: 1) subjective sleep quality, 2) sleep latency, 3) sleep duration, 4) sleep efficiency, 5) sleep disturbances, 6) sleep medication usage, and 7) daytime dysfunction. Each item is scored 0-3 (0 = very good, 1 = fairly good, 2= fairly bad, 3=very bad). Higher scores indicate more sleep dysfunction. Score range is 0-21. | Visit 1 (Baseline) | |
| Secondary | Pittsburgh Sleep Quality Index (PSQI) | The PSQI assesses sleep quality. It is an 19 item self-reported measure that is comprised of seven component scores: 1) subjective sleep quality, 2) sleep latency, 3) sleep duration, 4) sleep efficiency, 5) sleep disturbances, 6) sleep medication usage, and 7) daytime dysfunction. Each item is scored 0-3 (0 = very good, 1 = fairly good, 2= fairly bad, 3=very bad). Higher scores indicate more sleep dysfunction. Score range is 0-21. | At study completion, an average of 30 days after Visit 1 | |
| Secondary | Timed-Up-and-Go | Walking balance test, distance of 3 meters (10 feet). Participants are timed. Participants are seated in a chair, instructed to get up, walk 3 meters (marked on floor or by cone), round the cone, return to the chair and sit back down. Participants will repeat this 3 times, and we will use the average time. < 10 second = normal, <20 seconds, good mobility, <30 second, problems/may require aid. Higher scores indicating more problems with mobility. | Visit 1 (Baseline) | |
| Secondary | Timed-Up-and-Go | Walking balance test, distance of 3 meters (10 feet). Participants are timed. Participants are seated in a chair, instructed to get up, walk 3 meters (marked on floor or by cone), round the cone, return to the chair and sit back down. Participants will repeat this 3 times, and we will use the average time. < 10 second = normal, <20 seconds, good mobility, <30 second, problems/may require aid. Higher scores indicating more problems with mobility. | At study completion, an average of 30 days after Visit 1 | |
| Secondary | Patient's Global Impression of Change (PGIC) | PGIC is a self-reported assessment of change. Participants rate their impression of how much better they feel on a 7 point likert scale. It is a 1 item survey, with higher scores representing no change and associated with feeling worse. (Responses 1=much improved, 2=minimally improved, 3=no change, 4=minimally worse, 5=much worse, 6=very much worse). | Daily between Visit 1 and study completion, an average of 30 days | |
| Secondary | Percent Back to Normal | Subject rates on a scale from 0% to 100% how much they feel like they are back to normal (before injury) | Daily between Visit 1 and study completion, an average of 30 days |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04586179 -
A Comparison Between Cardiovascular Exercise Modes Following Sport Related Concussion
|
N/A | |
| Not yet recruiting |
NCT05943561 -
Biomarkers in Concussion
|
||
| Completed |
NCT03236389 -
Brain Dynamics in Response to Jugular Vein Compression
|
N/A | |
| Completed |
NCT02721537 -
Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes
|
N/A | |
| Completed |
NCT01832714 -
Assessment of Oculomotor, Vestibular and Reaction Time Response Following a Concussive Event
|
||
| Completed |
NCT04560400 -
Reverse King-Devick Test and History of Multiple Concussions
|
N/A | |
| Completed |
NCT03678077 -
Trends in Cohabitation Status, Academic Achievement and Socio-economic Indicators After Mild Traumatic Brain Injury
|
||
| Recruiting |
NCT05262361 -
Persistent Post-Concussion Symptoms With Convergence Insufficiency
|
N/A | |
| Recruiting |
NCT05105802 -
Mindfulness-Based Intervention for Mild Traumatic Brain Injury
|
N/A | |
| Terminated |
NCT03123822 -
Spectacles Lens in Concussed Kids
|
N/A | |
| Completed |
NCT04641832 -
The Combined Effect of Chronic Cannabis Use and Subconcussive Head Impacts on Brain Health
|
N/A | |
| Completed |
NCT04074486 -
Evaluation and Validation of a Multimodal Brain Function Biomarker With NPC
|
||
| Withdrawn |
NCT04578743 -
Exercise as Concussion Therapy Trial- 2
|
Phase 2 | |
| Completed |
NCT03170856 -
The Effects of a Sub-maximal Exercise Program on Adolescents Who Sustained a Concussion
|
N/A | |
| Completed |
NCT03671083 -
Validation of Brain Function Assessment Algorithm for mTBI/Concussion
|
||
| Completed |
NCT05069948 -
Delivery of Digital Cognitive Behavioural Therapy Following Concussion
|
N/A | |
| Recruiting |
NCT03889483 -
Neurophysiological Measurements Using the NeuroCatch™ Platform in Pediatric Concussion
|
N/A | |
| Withdrawn |
NCT02959294 -
Use of Adipose-Derived Stem/Stromal Cells in Concussion and Traumatic Brain Injuries
|
Early Phase 1 | |
| Recruiting |
NCT06093295 -
Non-invasive Brain Stimulation and Injury Risk Biomechanics
|
N/A | |
| Completed |
NCT02280304 -
Meditation in Veterans With PTSD and Mild TBI
|
N/A |